Skip to main content
Erschienen in: World Journal of Urology 6/2006

01.12.2006 | Topic Paper

Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)

verfasst von: Aksam A. Yassin, Farid Saad

Erschienen in: World Journal of Urology | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Recently, testosterone undecanoate (TU), a new parenteral testosterone (T) preparation has been introduced. Two of its distinctive features are (a) its prolonged action: after two initial loading injections 6 weeks apart, usually only one injection every 12 weeks is needed (b) over the full interval between two injections, plasma T levels are in the physiological range. New research presents convincing evidence that T has profound effects on tissues of the penis involved in the mechanism of erection and that testosterone deficiency impairs the anatomical and physiological substrate of erectile capacity, which is, at least, in part reversible upon androgen therapy. Our studies with TU demonstrated that venous leakage could be corrected with T treatment in a number of patients. We further could show that sexual functions, in a substantial number of elderly men, can be restored with treatment with T only. So, these results argue for determination of T levels in elderly men with sexual problems. If the levels are subnormal, T treatment is warranted.
Literatur
1.
Zurück zum Zitat Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev 26(6):833–876CrossRefPubMed Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev 26(6):833–876CrossRefPubMed
2.
Zurück zum Zitat Park K, Ku JH, Kim SW, Paick JS (2005) Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 95(3):366–370CrossRefPubMed Park K, Ku JH, Kim SW, Paick JS (2005) Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. BJU Int 95(3):366–370CrossRefPubMed
3.
Zurück zum Zitat Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J (2005) Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90(7):3838–3846CrossRefPubMed Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J (2005) Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 90(7):3838–3846CrossRefPubMed
4.
Zurück zum Zitat Gooren LJ, Saad F (2006) Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 8(1):3–9CrossRefPubMed Gooren LJ, Saad F (2006) Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 8(1):3–9CrossRefPubMed
5.
Zurück zum Zitat Yassin AA, Saad F (2006) Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia 38(1):34–37CrossRefPubMed Yassin AA, Saad F (2006) Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia 38(1):34–37CrossRefPubMed
6.
Zurück zum Zitat Yassin AA, Saad F, Traish A (2006) Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 3(4):727–735CrossRefPubMed Yassin AA, Saad F, Traish A (2006) Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 3(4):727–735CrossRefPubMed
7.
Zurück zum Zitat Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89(11):5429–5434CrossRefPubMed Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89(11):5429–5434CrossRefPubMed
8.
Zurück zum Zitat Harle L, Basaria S, Dobs AS (2005) Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6(10):1751–1759CrossRefPubMed Harle L, Basaria S, Dobs AS (2005) Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6(10):1751–1759CrossRefPubMed
9.
Zurück zum Zitat Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004) Pharmacology of testosterone preparations. In: Nieschlag E, BehreHM (eds) Testosterone, action, deficiency, substitution. Cambridge University Press, UK, pp. 405–444 Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004) Pharmacology of testosterone preparations. In: Nieschlag E, BehreHM (eds) Testosterone, action, deficiency, substitution. Cambridge University Press, UK, pp. 405–444
10.
Zurück zum Zitat Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84(10):3469–3478CrossRefPubMed Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84(10):3469–3478CrossRefPubMed
11.
Zurück zum Zitat Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140(5):414–419CrossRefPubMed Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140(5):414–419CrossRefPubMed
12.
Zurück zum Zitat von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23(3):419–425 von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23(3):419–425
13.
Zurück zum Zitat Dobs AS, Matsumoto AM, Wang C, Kipnes MS (2004) Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 20(5):729–738CrossRefPubMed Dobs AS, Matsumoto AM, Wang C, Kipnes MS (2004) Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 20(5):729–738CrossRefPubMed
14.
Zurück zum Zitat Zitzmann MNE (2006) Long-term experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal men. Aging Male 9 (suppl 1):5 Zitzmann MNE (2006) Long-term experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal men. Aging Male 9 (suppl 1):5
15.
Zurück zum Zitat Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48(1):1–4CrossRefPubMed Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48(1):1–4CrossRefPubMed
16.
Zurück zum Zitat Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA (2005) Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 96(6):773–776CrossRefPubMed Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA (2005) Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy? BJU Int 96(6):773–776CrossRefPubMed
17.
Zurück zum Zitat Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H (2005) Reasonable delay of surgical treatment in men with localized prostate cancer—impact on prognosis? Eur Urol 47(6):756–760CrossRefPubMed Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H (2005) Reasonable delay of surgical treatment in men with localized prostate cancer—impact on prognosis? Eur Urol 47(6):756–760CrossRefPubMed
18.
Zurück zum Zitat Yassin A, Saad F (2005) Modulation of erectile function with long acting testosterone injection (Nebido) i.m. in hypogonadal patients. Int J Androl 28(suppl 1):53 Yassin A, Saad F (2005) Modulation of erectile function with long acting testosterone injection (Nebido) i.m. in hypogonadal patients. Int J Androl 28(suppl 1):53
19.
Zurück zum Zitat Yassin A, Saad F. Improvement of sexual functions in men with late onset hypogonadism treated with testosterone only. J Sex Med 2006(September 2006) Yassin A, Saad F. Improvement of sexual functions in men with late onset hypogonadism treated with testosterone only. J Sex Med 2006(September 2006)
20.
Zurück zum Zitat Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A (2003) Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58(5):632–8CrossRef Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A (2003) Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 58(5):632–8CrossRef
21.
Zurück zum Zitat Burnett A (2004) Novel nitric oxide signaling mechanisms regualte the erectile response. Int J Impot Res 16(suppl 1):15–19CrossRef Burnett A (2004) Novel nitric oxide signaling mechanisms regualte the erectile response. Int J Impot Res 16(suppl 1):15–19CrossRef
22.
Zurück zum Zitat Traish AM, Guay AT (2006) Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3(3):382–404; discussion 404–407 Traish AM, Guay AT (2006) Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 3(3):382–404; discussion 404–407
23.
Zurück zum Zitat Traish AM, Toselli P, Jeong SJ, Kim NN (2005) Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 26(2):242–248PubMed Traish AM, Toselli P, Jeong SJ, Kim NN (2005) Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 26(2):242–248PubMed
24.
Zurück zum Zitat Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM (2004) Endocrine aspects of sexual dysfunction in men. J Sex Med 1(1):69–81CrossRefPubMed Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman JM, Tan HM (2004) Endocrine aspects of sexual dysfunction in men. J Sex Med 1(1):69–81CrossRefPubMed
25.
Zurück zum Zitat Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J (2006) EAU Guidelines on erectile dysfunction: an update. Eur Urol 49(5):806–815CrossRefPubMed Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J (2006) EAU Guidelines on erectile dysfunction: an update. Eur Urol 49(5):806–815CrossRefPubMed
Metadaten
Titel
Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)
verfasst von
Aksam A. Yassin
Farid Saad
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 6/2006
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0120-0

Weitere Artikel der Ausgabe 6/2006

World Journal of Urology 6/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.